<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37243092</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Methodological Framework for Assessing the Benefit of SARS-CoV-2 Vaccination following Previous Infection: Case Study of Five- to Eleven-Year-Olds.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">988</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11050988</ELocationID><Abstract><AbstractText>Vaccination rates against SARS-CoV-2 in children aged five to eleven years remain low in many countries. The current benefit of vaccination in this age group has been questioned given that the large majority of children have now experienced at least one SARS-CoV-2 infection. However, protection from infection, vaccination or both wanes over time. National decisions on offering vaccines to this age group have tended to be made without considering time since infection. There is an urgent need to evaluate the additional benefits of vaccination in previously infected children and under what circumstances those benefits accrue. We present a novel methodological framework for estimating the potential benefits of COVID-19 vaccination in previously infected children aged five to eleven, accounting for waning. We apply this framework to the UK context and for two adverse outcomes: hospitalisation related to SARS-CoV-2 infection and Long Covid. We show that the most important drivers of benefit are: the degree of protection provided by previous infection; the protection provided by vaccination; the time since previous infection; and future attack rates. Vaccination can be very beneficial for previously infected children if future attack rates are high and several months have elapsed since the previous major wave in this group. Benefits are generally larger for Long Covid than hospitalisation, because Long Covid is both more common than hospitalisation and previous infection offers less protection against it. Our framework provides a structure for policy makers to explore the additional benefit of vaccination across a range of adverse outcomes and different parameter assumptions. It can be easily updated as new evidence emerges.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pagel</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2857-1628</Identifier><AffiliationInfo><Affiliation>Clinical Operational Research Unit, Department of Mathematics, University College London (UCL), London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilde</LastName><ForeName>Harrison</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4391-8204</Identifier><AffiliationInfo><Affiliation>Department of Statistics, University of Warwick, Coventry CV4 7AL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Health Informatics, University College London (UCL), London NW1 2DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0903-5395</Identifier><AffiliationInfo><Affiliation>UCL Institute of Health Informatics, University College London (UCL), London NW1 2DA, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Research and Innovation Centre for Doctoral Training in AI-enabled Healthcare Systems, University College London (UCL), London WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University College London Hospitals Biomedical Research Centre, University College London (UCL), London W1T 7DN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateen</LastName><ForeName>Bilal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>UCL Institute of Health Informatics, University College London (UCL), London NW1 2DA, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University College London Hospitals Biomedical Research Centre, University College London (UCL), London W1T 7DN, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Trust, London NW1 2BE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biomedical Research Centre, Great Ormond Street Hospital for Children, London WC1N 3JH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, University College London (UCL), London WC1E 6DD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_20058</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SP/19/3/34678</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">health policy</Keyword><Keyword MajorTopicYN="N">mathematical modelling</Keyword><Keyword MajorTopicYN="N">paediatric vaccines</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37243092</ArticleId><ArticleId IdType="pmc">PMC10220644</ArticleId><ArticleId IdType="doi">10.3390/vaccines11050988</ArticleId><ArticleId IdType="pii">vaccines11050988</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walter E.B., Talaat K.R., Sabharwal C., Gurtman A., Lockhart S., Paulsen G.C., Barnett E.D., Mu&#xf1;oz F.M., Maldonado Y., Pahud B.A., et al. Evaluation of the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022;386:35&#x2013;46. doi: 10.1056/NEJMoa2116298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116298</ArticleId><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco C., Del Manso M., Mateo-Urdiales A., Rota M.C., Petrone D., Riccardo F., Bella A., Siddu A., Battilomo S., Proietti V., et al. Effectiveness of BNT162b2 Vaccine against SARS-CoV-2 Infection and Severe COVID-19 in Children Aged 5&#x2013;11 Years in Italy: A Retrospective Analysis of January&#x2013;April, 2022. Lancet. 2022;400:97&#x2013;103. doi: 10.1016/S0140-6736(22)01185-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01185-0</ArticleId><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell A.A., Kirsebom F., Stowe J., Ramsay M.E., Lopez-Bernal J., Andrews N., Ladhani S.N. Protection against Symptomatic Infection with Delta (B.1.617.2) and Omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 Variants after Previous Infection and Vaccination in Adolescents in England, August, 2021&#x2013;March, 2022: A National, Observational, Test-Negative, Case-Control Study. Lancet Infect. Dis. 2022;23:435&#x2013;444. doi: 10.1016/S1473-3099(22)00729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00729-0</ArticleId><ArticleId IdType="pmc">PMC10032664</ArticleId><ArticleId IdType="pubmed">36436536</ArticleId></ArticleIdList></Reference><Reference><Citation>ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization|CDC.  [(accessed on 26 July 2022)]; Available online:  https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-pfizer-age-5-11-eua-etr.html.</Citation></Reference><Reference><Citation>Molteni E., Canas L.S., Kl&#xe4;ser K., Deng J., Bhopal S.S., Hughes R.C., Chen L., Murray B., Kerfoot E., Antonelli M., et al. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study. Lancet Reg. Health Eur. 2022 doi: 10.1016/j.lanepe.2022.100429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100429</ArticleId><ArticleId IdType="pmc">PMC9263281</ArticleId><ArticleId IdType="pubmed">35821715</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano L.D. Effectiveness of BNT162b2 (Pfizer-BioNTech) MRNA Vaccination Against Multisystem Inflammatory Syndrome in Children among Persons Aged 12&#x2013;18 Years&#x2014;United States, July&#x2013;December 2021. MMWR Morb. Mortal. Wkly. Rep. 2022;71:52. doi: 10.15585/mmwr.mm7102e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e1</ArticleId><ArticleId IdType="pmc">PMC8757620</ArticleId><ArticleId IdType="pubmed">35025852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.-Y., Gu Y., Xu Y., Zeng D., Wheeler B., Young H., Sunny S.K., Moore Z. Effects of Vaccination and Previous Infection on Omicron Infections in Children. N. Engl. J. Med. 2022;387:1141&#x2013;1143. doi: 10.1056/NEJMc2209371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209371</ArticleId><ArticleId IdType="pmc">PMC9511630</ArticleId><ArticleId IdType="pubmed">36069811</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.-L., Chua G.T., Lu L., Chan B.P.-C., Wong J.S.-C., Chow C.C.-K., Yu T.-C., Leung A.S.-Y., Lam S.-Y., Wong T.-W., et al. Omicron Variant Susceptibility to Neutralizing Antibodies Induced in Children by Natural SARS-CoV-2 Infection or COVID-19 Vaccine. Emerg. Microbes Infect. 2022;11:543&#x2013;547. doi: 10.1080/22221751.2022.2035195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2035195</ArticleId><ArticleId IdType="pmc">PMC8843159</ArticleId><ArticleId IdType="pubmed">35084295</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., et al. Protective Effectiveness of Previous SARS-CoV-2 Infection and Hybrid Immunity against the Omicron Variant and Severe Disease: A Systematic Review and Meta-Regression. Lancet Infect. Dis. 2023;23:556&#x2013;567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg S.P., de Gier B., Eggink D., Ali L., Vlaemynck B., Schepers R., Covid R., Hahn&#xe9; S.J.M. Protection of COVID-19 Vaccination and Previous Infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 Infections. Nat. Commun. 2022;13:4738. doi: 10.1038/s41467-022-31838-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31838-8</ArticleId><ArticleId IdType="pmc">PMC9373894</ArticleId><ArticleId IdType="pubmed">35961956</ArticleId></ArticleIdList></Reference><Reference><Citation>Price A.M., Olson S.M., Newhams M.M., Halasa N.B., Boom J.A., Sahni L.C., Pannaraj P.S., Irby K., Bline K.E., Maddux A.B., et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N. Engl. J. Med. 2022;386:1899&#x2013;1909. doi: 10.1056/NEJMoa2202826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2202826</ArticleId><ArticleId IdType="pmc">PMC9006785</ArticleId><ArticleId IdType="pubmed">35353976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.H.X., Cook A.R., Heng D., Ong B., Lye D.C., Tan K.B. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022;387:525&#x2013;532. doi: 10.1056/NEJMoa2203209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203209</ArticleId><ArticleId IdType="pmc">PMC9342421</ArticleId><ArticleId IdType="pubmed">35857701</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming-Dutra K.E., Britton A., Shang N., Derado G., Link-Gelles R., Accorsi E.K., Smith Z.R., Miller J., Verani J.R., Schrag S.J. Association of Prior BNT162b2 COVID-19 Vaccination with Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA. 2022;327:2210&#x2013;2219. doi: 10.1001/jama.2022.7493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.7493</ArticleId><ArticleId IdType="pmc">PMC9107063</ArticleId><ArticleId IdType="pubmed">35560036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorabawila V., Hoefer D., Bauer U.E., Bassett M.T., Lutterloh E., Rosenberg E.S. Risk of Infection and Hospitalization among Vaccinated and Unvaccinated Children and Adolescents in New York after the Emergence of the Omicron Variant. JAMA. 2022;327:2242&#x2013;2244. doi: 10.1001/jama.2022.7319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.7319</ArticleId><ArticleId IdType="pmc">PMC9107062</ArticleId><ArticleId IdType="pubmed">35559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Cusenza F., Passadore L., Bonanno F., De Guido C., Esposito S. Duration of Immunity to SARS-CoV-2 in Children after Natural Infection or Vaccination in the Omicron and Pre-Omicron Era: A Systematic Review of Clinical and Immunological Studies. Front. Immunol. 2023;13:7883. doi: 10.3389/fimmu.2022.1024924.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1024924</ArticleId><ArticleId IdType="pmc">PMC9874918</ArticleId><ArticleId IdType="pubmed">36713374</ArticleId></ArticleIdList></Reference><Reference><Citation>Stich M., Benning L., Speer C., Garbade S.F., Bartenschlager M., Kim H., Jeltsch K., Tabatabai J., Niesert M., Janda A., et al. Live-Virus Neutralization of the Omicron Variant in Children and Adults 14 Months after SARS-CoV-2 Wild-Type Infection. J. Med. Virol. 2023;95:e28582. doi: 10.1002/jmv.28582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28582</ArticleId><ArticleId IdType="pubmed">36794653</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Infection Survey, UK Statistical Bulletins&#x2014;Office for National Statistics.  [(accessed on 18 March 2021)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/previousReleases.</Citation></Reference><Reference><Citation>COVID-19 Schools Infection Survey, England: Pupil Antibody Data, January to February 2022&#x2014;Office for National Statistics.  [(accessed on 1 August 2022)]; Available online:  https://www.ons.gov.uk/releases/covid19schoolsinfectionsurveyenglandpupilantibodydatajanuarytofebruary2022.</Citation></Reference><Reference><Citation>Toh Z.Q., Anderson J., Mazarakis N., Neeland M., Higgins R.A., Rautenbacher K., Dohle K., Nguyen J., Overmars I., Donato C., et al. Comparison of Seroconversion in Children and Adults with Mild COVID-19. JAMA Netw. Open. 2022;5:e221313. doi: 10.1001/jamanetworkopen.2022.1313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.1313</ArticleId><ArticleId IdType="pmc">PMC8908077</ArticleId><ArticleId IdType="pubmed">35262717</ArticleId></ArticleIdList></Reference><Reference><Citation>Real-Time Epidemiological Estimates from ONS Community Infection Survey Data.  [(accessed on 5 October 2022)].  Available online:  https://epiforecasts.io/inc2prev/report.</Citation></Reference><Reference><Citation>Coronavirus (COVID-19) Infection Survey Technical Article: Cumulative Incidence of the Percentage of People Who Have Been Infected with COVID-19 by Variant and Age, England&#x2014;Office for National Statistics.  [(accessed on 11 February 2023)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticlecumulativeincidenceofthenumberofpeoplewhohavebeeninfectedwithcovid19byvariantandageengland/9february2023#data-sources-and-quality.</Citation></Reference><Reference><Citation>Commissioner O. of the FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age.  [(accessed on 22 December 2021)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.</Citation></Reference><Reference><Citation>Reuters Israel Says Children Aged 5-11 Can Receive COVID-19 Vaccine. Reuters. 2021</Citation></Reference><Reference><Citation>EMA  Comirnaty COVID-19 Vaccine: EMA Recommends Approval for Children Aged 5 to 11.  [(accessed on 11 October 2022)].  Available online:  https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11.</Citation></Reference><Reference><Citation>UK Regulator Approves Use of Pfizer/BioNTech Vaccine in 5 to 11-Year Olds.  [(accessed on 11 October 2022)]; Available online:  https://www.gov.uk/government/news/uk-regulator-approves-use-of-pfizerbiontech-vaccine-in-5-to-11-year-olds.</Citation></Reference><Reference><Citation>COVID-19: The Green Book, Chapter 14a.  [(accessed on 27 February 2023)]; Available online:  https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.</Citation></Reference><Reference><Citation>Vaccinations in England|Coronavirus in the UK.  [(accessed on 3 April 2023)]; Available online:  https://coronavirus.data.gov.uk/details/vaccinations?areaType=nation&amp;areaName=England.</Citation></Reference><Reference><Citation>Cohen-Stavi C.J., Magen O., Barda N., Yaron S., Peretz A., Netzer D., Giaquinto C., Judd A., Leibovici L., Hern&#xe1;n M.A., et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022;387:227&#x2013;236. doi: 10.1056/NEJMoa2205011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2205011</ArticleId><ArticleId IdType="pmc">PMC9258754</ArticleId><ArticleId IdType="pubmed">35767475</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis N., Correspondent N.D.S. Rising UK Covid Levels: What&#x2019;s Driving It and What Will Happen next? Guardian. 2022</Citation></Reference><Reference><Citation>CovSPECTRUM.  [(accessed on 3 April 2023)].  Available online:  https://cov-spectrum.org.</Citation></Reference><Reference><Citation>Tuekprakhon A., Nutalai R., Dijokaite-Guraliuc A., Zhou D., Ginn H.M., Selvaraj M., Liu C., Mentzer A.J., Supasa P., Duyvesteyn H.M.E., et al. Antibody Escape of SARS-CoV-2 Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum. Cell. 2022;185:2422&#x2013;2433.e13. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. COVID-19: Sharp Rise in Infections Seen across the UK. BMJ. 2022;378:o1638. doi: 10.1136/bmj.o1638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1638</ArticleId><ArticleId IdType="pubmed">35787528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Acute and Postacute Sequelae Associated with SARS-CoV-2 Reinfection. Nat. Med. 2022;28:2398&#x2013;2405. doi: 10.1038/s41591-022-02051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>New-Onset, Self-Reported Long COVID after Coronavirus (COVID-19) Reinfection&#x2014;Office for National Statistics.  [(accessed on 27 February 2023)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/newonsetselfreportedlongcovidaftercoronaviruscovid19reinfection.</Citation></Reference><Reference><Citation>Reynolds C.J., Pade C., Gibbons J.M., Otter A.D., Lin K.-M., Sandoval D.M., Pieper F.P., Butler D.K., Liu S., Joy G., et al. Immune Boosting by B.1.1.529 (Omicron) Depends on Previous SARS-CoV-2 Exposure. Science. 2022;377:eabq1841. doi: 10.1126/science.abq1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchering R.K., Mullany L.C., Howerton E., Chinazzi M., Smith C.P., Qin M., Reich N.G., Contamin L., Levander J., Kerr J., et al. Impact of SARS-CoV-2 Vaccination of Children Ages 5&#x2013;11 Years on COVID-19 Disease Burden and Resilience to New Variants in the United States, November 2021&#x2013;March 2022: A Multi-Model Study. Lancet Reg. Health Am. 2023;17:100398. doi: 10.1016/j.lana.2022.100398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100398</ArticleId><ArticleId IdType="pmc">PMC9679449</ArticleId><ArticleId IdType="pubmed">36437905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes M.T., Good M.F. Vaccinating Children against COVID-19: Commentary and Mathematical Modeling. mBio. 2022;13:e03789-21. doi: 10.1128/mbio.03789-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03789-21</ArticleId><ArticleId IdType="pmc">PMC8764932</ArticleId><ArticleId IdType="pubmed">35040706</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling M.J., Moore S.E. An Assessment of the Vaccination of School-Aged Children in England against SARS-CoV-2. BMC Med. 2022;20:196. doi: 10.1186/s12916-022-02379-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02379-0</ArticleId><ArticleId IdType="pmc">PMC9113775</ArticleId><ArticleId IdType="pubmed">35581585</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S., Hill E.M., Tildesley M.J., Dyson L., Keeling M.J. Vaccination and Non-Pharmaceutical Interventions for COVID-19: A Mathematical Modelling Study. Lancet Infect. Dis. 2021;21:793&#x2013;802. doi: 10.1016/S1473-3099(21)00143-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00143-2</ArticleId><ArticleId IdType="pmc">PMC7972312</ArticleId><ArticleId IdType="pubmed">33743847</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling M.J., Tildesley M.J., Atkins B.D., Penman B., Southall E., Guyver-Fletcher G., Holmes A., McKimm H., Gorsich E.E., Hill E.M., et al. The Impact of School Reopening on the Spread of COVID-19 in England. Philos. Trans. R. Soc. B Biol. Sci. 2021;376:20200261. doi: 10.1098/rstb.2020.0261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2020.0261</ArticleId><ArticleId IdType="pmc">PMC8165595</ArticleId><ArticleId IdType="pubmed">34053259</ArticleId></ArticleIdList></Reference><Reference><Citation>JCVI  Statement on Vaccination of Children Aged 5 to 11 Years Old.  [(accessed on 26 July 2022)]; Available online:  https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-aged-5-to-11/jcvi-statement-on-vaccination-of-children-aged-5-to-11-years-old.</Citation></Reference><Reference><Citation>Molloy E.J., Nakra N., Gale C., Dimitriades V.R., Lakshminrusimha S. Multisystem Inflammatory Syndrome in Children (MIS-C) and Neonates (MIS-N) Associated with COVID-19: Optimizing Definition and Management. Pediatr. Res. 2022;93:1499&#x2013;1508. doi: 10.1038/s41390-022-02263-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-022-02263-w</ArticleId><ArticleId IdType="pmc">PMC9436161</ArticleId><ArticleId IdType="pubmed">36050390</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M., Recher M., Hubert H., Javouhey E., Fl&#xe9;chelles O., Leteurtre S., Angoulvant F. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA. 2021;327:281&#x2013;283. doi: 10.1001/jama.2021.23262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23262</ArticleId><ArticleId IdType="pmc">PMC8689418</ArticleId><ArticleId IdType="pubmed">34928295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde H., Tomlinson C., Mateen B., Selby D., Kanthimathinathan H.K., Ramnarayan P., du Pr&#xe9; P., Johnson M., Pathan N., Gonzalez-Izquierdo A., et al. Hospital Admissions Linked to SARS-CoV-2 Infection in Children: A Cohort Study of 3.2 Million First Ascertained Infections in England. BMJ Br. Med. J. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10318942</ArticleId><ArticleId IdType="pubmed">37407076</ArticleId></ArticleIdList></Reference><Reference><Citation>Estimates of the Population for the UK, England, Wales, Scotland and Northern Ireland&#x2014;Office for National Statistics.  [(accessed on 9 February 2023)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland.</Citation></Reference><Reference><Citation>Watanabe A., Kani R., Iwagami M., Takagi H., Yasuhara J., Kuno T. Assessment of Efficacy and Safety of MRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2023;177:384&#x2013;394. doi: 10.1001/jamapediatrics.2022.6243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.6243</ArticleId><ArticleId IdType="pmc">PMC9871947</ArticleId><ArticleId IdType="pubmed">36689319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S., Lee G.M., Razzaghi H., Lorman V., Mejias A., Pajor N.M., Thacker D., Webb R., Dickinson K., Bailey L.C., et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr. 2022;176:1000&#x2013;1009. doi: 10.1001/jamapediatrics.2022.2800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.2800</ArticleId><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkenborg Berg S., Palm P., Nygaard U., Bundgaard H., Petersen M.N.S., Rosenkilde S., Thorsted A.B., Ersb&#xf8;ll A.K., Thygesen L.C., Nielsen S.D., et al. Long COVID Symptoms in SARS-CoV-2-Positive Children Aged 0&#x2013;14 Years and Matched Controls in Denmark (LongCOVIDKidsDK): A National, Cross-Sectional Study. Lancet Child Adolesc. Health. 2022;6:614&#x2013;623. doi: 10.1016/S2352-4642(22)00154-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00154-7</ArticleId><ArticleId IdType="pmc">PMC9221683</ArticleId><ArticleId IdType="pubmed">35752194</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-COVID-19 Conditions in Children and Adolescents.  [(accessed on 3 October 2022)].  Available online:  http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/post-covid-19-conditions-in-children-and-adolescents/</Citation></Reference><Reference><Citation>Funk A.L., Kuppermann N., Florin T.A., Tancredi D.J., Xie J., Kim K., Finkelstein Y., Neuman M.I., Salvadori M.I., Yock-Corrales A., et al. Post&#x2013;COVID-19 Conditions among Children 90 Days after SARS-CoV-2 Infection. JAMA Netw. Open. 2022;5:e2223253. doi: 10.1001/jamanetworkopen.2022.23253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.23253</ArticleId><ArticleId IdType="pmc">PMC9308058</ArticleId><ArticleId IdType="pubmed">35867061</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell A.C., Lancaster T., Bruton R., Ireland G., Bentley C., Sylla P., Zuo J., Scott S., Jadir A., Begum J., et al. Immunology. Wiley; Hoboken, NJ, USA: 2022. Primary Omicron Infection Elicits Weak Antibody Response but Robust Cellular Immunity in Children.</Citation></Reference><Reference><Citation>COVID-19 Vaccination Protects against Long COVID.  [(accessed on 24 October 2022)].  Available online:  https://www.gavi.org/vaccineswork/covid-19-vaccination-protects-against-long-covid.</Citation></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K., Glasziou P. Effect of COVID-19 Vaccination on Long Covid: Systematic Review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Sudry T., Flaks-Manov N., Yehezkelli Y., Kalkstein N., Akiva P., Ekka-Zohar A., David S.S.B., Lerner U., Bivas-Benita M., et al. Long Covid Outcomes at One Year after Mild SARS-CoV-2 Infection: Nationwide Cohort Study. BMJ. 2023;380:e072529. doi: 10.1136/bmj-2022-072529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehrani S., Killander A., &#xc5;strand P., Jakobsson J., Gille-Johnson P. Risk Factors for Death in Adult COVID-19 Patients: Frailty Predicts Fatal Outcome in Older Patients. Int. J. Infect. Dis. 2021;102:415&#x2013;421. doi: 10.1016/j.ijid.2020.10.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.071</ArticleId><ArticleId IdType="pmc">PMC7833745</ArticleId><ArticleId IdType="pubmed">33130213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.-T., Perrodeau E., Saldanha J., Pane I., Ravaud P. Efficacy of First Dose of COVID-19 Vaccine versus No Vaccination on Symptoms of Patients with Long Covid: Target Trial Emulation Based on ComPaRe e-Cohort. BMJ Med. 2023;2:e000229. doi: 10.1136/bmjmed-2022-000229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000229</ArticleId><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Attendance in Education and Early Years Settings during the Coronavirus (COVID-19) Pandemic, Week 50 2021.  [(accessed on 22 December 2021)]; Available online:  https://explore-education-statistics.service.gov.uk/find-statistics/attendance-in-education-and-early-years-settings-during-the-coronavirus-covid-19-outbreak.</Citation></Reference><Reference><Citation>Liu J., Lee M., Gershenson S. The Short- and Long-Run Impacts of Secondary School Absences. J. Public Econ. 2021;199:104441. doi: 10.1016/j.jpubeco.2021.104441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpubeco.2021.104441</ArticleId></ArticleIdList></Reference><Reference><Citation>New Recommendations for Vaccination against COVID-19&#x2014;The Public Health Agency of Sweden.  [(accessed on 3 May 2023)].  Available online:  https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/covid-19/vaccination-against-covid-19/order-of-priority-for-covid-19-vaccine/</Citation></Reference><Reference><Citation>Vaccination against COVID-19.  [(accessed on 3 May 2023)].  Available online:  https://www.sst.dk/en/english/corona-eng/vaccination-against-covid-19.</Citation></Reference><Reference><Citation>Callaway E. COVID&#x2019;s Future: Mini-Waves Rather than Seasonal Surges. Nature. 2023;617:229&#x2013;230. doi: 10.1038/d41586-023-01437-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-01437-8</ArticleId><ArticleId IdType="pubmed">37127700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A., Denholm R., Hollings S., Cooper J., Ip S., Walker V., Denaxas S., Akbari A., Banerjee A., Whiteley W., et al. Linked Electronic Health Records for Research on a Nationwide Cohort of More than 54 Million People in England: Data Resource. BMJ. 2021;373:n826. doi: 10.1136/bmj.n826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n826</ArticleId><ArticleId IdType="pmc">PMC8413899</ArticleId><ArticleId IdType="pubmed">33827854</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson T., Stephenson T., Pereira S.P., Shafran R., De Stavola B., Rojas N., McOwat K., Simmons R., Zavala M., O&#x2019;Mahoney L., et al. Long COVID&#x2014;The Physical and Mental Health of Children and Non-Hospitalised Young People 3 Months after SARS-CoV-2 Infection; a National Matched Cohort Study (The CLoCk) Study. Lancet Child Adolesc. Health. 2021;6:230&#x2013;239. doi: 10.1016/S2352-4642(22)00022-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00022-0</ArticleId><ArticleId IdType="pmc">PMC8820961</ArticleId><ArticleId IdType="pubmed">35143770</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni E., Sudre C.H., Canas L.S., Bhopal S.S., Hughes R.C., Antonelli M., Murray B., Kl&#xe4;ser K., Kerfoot E., Chen L., et al. Illness Duration and Symptom Profile in Symptomatic UK School-Aged Children Tested for SARS-CoV-2. Lancet Child Adolesc. Health. 2021;5:708&#x2013;718. doi: 10.1016/S2352-4642(21)00198-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00198-X</ArticleId><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurdasani D., Akrami A., Bradley V.C., Costello A., Greenhalgh T., Flaxman S., McKee M., Michie S., Pagel C., Rasmussen S., et al. Long COVID in Children. Lancet Child Adolesc. Health. 2022;6:e2. doi: 10.1016/S2352-4642(21)00342-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00342-4</ArticleId><ArticleId IdType="pmc">PMC8673872</ArticleId><ArticleId IdType="pubmed">34921807</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>